發(fā)布時(shí)間：2018-05-24 21:04

  本文選題：前列腺癌 + 良性前列腺增生　； 參考：《中國(guó)免疫學(xué)雜志》2016年08期

【摘要】：目的:檢測(cè)前列腺癌患者miRNA-15a的表達(dá)情況,探討其在前列腺癌診斷的意義。方法:選擇2014年1月至2015年1月本院泌尿外科收治的前列腺癌患者血清及腫瘤組織36例,良性前列腺增生患者(Prostatic hyperplasia,BPH)血清40例,健康對(duì)照血清40例。miRNA-15a表達(dá)采用實(shí)時(shí)定量聚合酶鏈反應(yīng)(Real-time PCR)技術(shù)檢測(cè)。結(jié)果:miRNA-15a在前列腺癌患者、良性前列腺增生患者和健康對(duì)照血清的表達(dá)量分別為(0.193±0.081)、(0.359±0.04)和(0.376±0.037),miRNA-15a在前列腺癌患者血清中的表達(dá)量顯著低于良性前列腺增生患者和健康對(duì)照(P0.05),在BPH組和對(duì)照組中的表達(dá)差異無統(tǒng)計(jì)學(xué)意義(P0.05),前列腺癌患者血清miRNA-15a表達(dá)在不同PSA表達(dá)水平、Gleason評(píng)分、臨床分期、有無遠(yuǎn)處轉(zhuǎn)移之間差異有統(tǒng)計(jì)學(xué)意義(P0.05),與其他病理因素?zé)o關(guān)(P0.05);前列腺癌患者腫瘤組織中的miRNA-15a的表達(dá)與PSA表達(dá)水平、Gleason評(píng)分、臨床分期、有無遠(yuǎn)處轉(zhuǎn)移之間差異有統(tǒng)計(jì)學(xué)意義(P0.05),與其他病理因素?zé)o關(guān)(P0.05)。結(jié)論:miRNA-15a低表達(dá)參與了前列腺癌的發(fā)生、發(fā)展過程,是前列腺癌輔助診斷及治療的潛在的指標(biāo)。
[Abstract]:Objective: to detect the expression of miRNA-15a in patients with prostate cancer and to explore its significance in the diagnosis of prostate cancer. Methods: 36 patients with prostate cancer, 40 cases of benign prostatic hyperplasia (Prostatic hyperplasia, BPH), 40 cases of healthy control serum,.MiR were selected from January 2014 to January 2015. The expression of NA-15a was detected by real-time quantitative polymerase chain reaction (Real-time PCR). Results: the expression of miRNA-15a in patients with prostate cancer, benign prostatic hyperplasia and healthy control was (0.193 + 0.081), (0.359 + 0.04) and (0.376 + 0.037). The expression of miRNA-15a in the serum of prostate cancer patients was significantly lower than that of benign prostatic cancer. There was no significant difference in the expression of prostatic hyperplasia and healthy control (P0.05) in the BPH group and the control group (P0.05). The expression of miRNA-15a in the serum of the prostate cancer patients at different levels of PSA expression, the Gleason score, the clinical stage, and the distant metastasis were statistically significant (P0.05), and were not related to other pathological factors (P0.05). The expression of miRNA-15a in the tumor tissues of the patients with adenocarcinoma was correlated with the level of PSA expression, Gleason score, clinical stage, and distant metastasis (P0.05), not related to other pathological factors (P0.05). Conclusion: the low expression of miRNA-15a is involved in the development of prostate cancer, the development process, and the potential of auxiliary diagnosis and treatment of prostate cancer. Indicators.
【作者單位】： 武漢科技大學(xué)醫(yī)學(xué)院;湖北省黃石市愛康醫(yī)院;
【分類號(hào)】：R737.25
，

本文編號(hào)：1930536